These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37318724)

  • 1. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
    Juarez-Vignon Whaley JJ; Afkhami M; Onyshchenko M; Massarelli E; Sampath S; Amini A; Bell D; Villaflor VM
    Curr Treat Options Oncol; 2023 Sep; 24(9):1138-1166. PubMed ID: 37318724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?
    Juarez-Vignon Whaley JJ; Afkhami M; Sampath S; Amini A; Bell D; Villaflor VM
    Curr Treat Options Oncol; 2023 Jul; 24(7):845-866. PubMed ID: 37145382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatiotemporal homogeneity and distinctness of the T-cell receptor β-chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas.
    Chung YL; Wu ML
    Int J Cancer; 2018 Aug; 143(3):610-620. PubMed ID: 29468660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
    Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
    Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
    Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
    Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic approaches in nasopharyngeal carcinoma.
    Chow JC; Ngan RK; Cheung KM; Cho WC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
    [No Abstract]   [Full Text] [Related]  

  • 9. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
    Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
    Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
    Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
    Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximal standard uptake values of
    Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
    BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
    Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
    JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
    Wang S; Chen S; Zhong Q; Liu Y
    J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
    Lin C; Lin K; Zhang B; Su Y; Guo Q; Lu T; Xu Y; Lin S; Zong J; Pan J
    Oncologist; 2022 Apr; 27(4):e340-e349. PubMed ID: 35380720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor 2 is highly sensitive and specific for Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Viswanathan K; Sadow PM
    Hum Pathol; 2021 Nov; 117():88-100. PubMed ID: 34416258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.